AbCellera Biologics

ABCL

The current AbCellera Biologics (ABCL) market capitalization is approximately $1.02B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, AbCellera Biologics's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:27 PM Eastern Time

In the most recently reported quarter, AbCellera Biologics (ABCL) generated $8.96M in revenue, representing a +37.62% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately $6.28M, implying an expected +23.21% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: December 31, 2025 at 7:11 PM Eastern Time

In the most recently reported fiscal year, AbCellera Biologics (ABCL) generated net income of $-0.16B, compared with $-0.15B in the prior fiscal year, representing a -11.24% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of $-0.19B. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: December 31, 2025 at 7:11 PM Eastern Time

According to its latest quarterly filing, AbCellera Biologics (ABCL) reported EBITDA of $-71.03M, representing a -25.18% year over year change. For the upcoming quarter, analyst consensus currently expects EBITDA of $-63.65M, reflecting assumptions around revenue trends, operating costs, scale efficiencies, and margin dynamics. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: December 31, 2025 at 7:11 PM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.15x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: December 31, 2025 at 7:11 PM Eastern Time

Based on the latest available data, AbCellera Biologics (ABCL) is currently trading at a last twelve months (LTM) P/E ratio of -5.90x. Looking forward, the stock trades at a next twelve months (NTM) P/E ratio of -4.68x, based on consensus earnings estimates. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: December 31, 2025 at 7:11 PM Eastern Time

AbCellera Biologics (ABCL) is currently scheduled to report its next earnings results on February 25, 2026. Earnings dates are subject to change and may be updated by the company with limited notice. Investors typically monitor upcoming earnings releases closely, as they can result in increased volatility depending on reported results, forward guidance, and management commentary. Last updated: December 31, 2025 at 11:27 PM Eastern Time

In the most recently reported quarter, AbCellera Biologics (ABCL) revenue was $8.96M, compared with analyst consensus expectations of $6.33M, representing a +41.41% revenue surprise versus expectations. Earnings per share (EPS) for the quarter were $-0.19, compared with consensus estimates of $-0.16, resulting in an -18.75% EPS surprise. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: December 31, 2025 at 7:11 PM Eastern Time

AbCellera Biologics's (ABCL) earnings reports, including quarterly and annual financial statements, are available through the company's official regulatory filings with the U.S. Securities and Exchange Commission (SEC). On Gainify, you can access AbCellera Biologics's full set of filings, including earnings releases, Form 10-Q, Form 10-K, and other disclosures, in one place: AbCellera Biologics SEC Filings These filings provide detailed information on AbCellera Biologics's financial performance and are considered the primary source of verified financial data for publicly traded companies.

AbCellera Biologics (ABCL) does not currently pay a dividend. Over the last twelve months (LTM), the company paid $0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: December 31, 2025 at 7:11 PM Eastern Time

Analyst assessments of whether AbCellera Biologics (ABCL) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: $3.42Consensus price target: $9.83Implied return: +187.52% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: December 31, 2025 at 7:11 PM Eastern Time

Based on the latest available analyst coverage, AbCellera Biologics (ABCL) currently carries a Buy consensus rating. Analysts' average ABCL price target is $9.83. Relative to the current share price of $3.42, this suggests a potential price change of approximately +187.52%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: December 31, 2025 at 7:11 PM Eastern Time

Like other publicly traded stocks, AbCellera Biologics (ABCL) shares are bought and sold on stock exchanges such as Nasdaq and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for AbCellera Biologics (ABCL) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add ABCL to your watchlist.

AbCellera Biologics trades under the ticker symbol ABCL on the Nasdaq stock exchange. The ticker ABCL is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, AbCellera Biologics (ABCL) employs approximately 596 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:27 PM Eastern Time

AbCellera Biologics (ABCL) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest AbCellera Biologics (ABCL) stock peers based on overlapping products, services, and competitive dynamics: (OABI)Codexis (CDXS)Schrödinger (SDGR)Eli Lilly and (LLY)Ginkgo Bioworks Holdings (DNA)XtalPi Holdings (2228)AbbVie (ABBV)Bruker (BRKR)Genscript Biotech (1548)Evotec (EVT) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to AbCellera Biologics.